<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265537</url>
  </required_header>
  <id_info>
    <org_study_id>H10-03047</org_study_id>
    <nct_id>NCT01265537</nct_id>
  </id_info>
  <brief_title>A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf</brief_title>
  <acronym>Astellas</acronym>
  <official_title>A Prospective, Open Label, Pilot Study Comparing the Use of Low-target Advagraf With Rabbit Antithymocyte Globulin Induction Versus Conventional Target Advagraf With Basiliximab Induction in a Steroid-avoidance Immunosuppressive Protocol for de Novo Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Canada, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While the incidence of acute rejection and early graft loss have improved dramatically with
      the advent of newer immunosuppressant medications, improvements in long-term patient and
      allograft survival after kidney transplantation have not been achieved. The specific drug
      combination that provides the best outcomes with the least amount of side effects is not
      known. Each kidney transplant center uses the combination of drugs that they believe is
      optimal. This study is about identifying whether drugs that are currently approved for use in
      kidney transplantation can be used in a new combination safely and with potentially fewer
      side effects than the drug combinations that are currently used at St. Paul's Hospital and
      other transplant centres.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose This study has been designed to test whether using Thymoglobulin with low dose
      tacrolimus and early steroid withdrawal will minimize both kidney rejection and the
      development of new onset diabetes after transplant (NODAT).

      Justification Experimental treatment is low target tacrolimus with thymoglobulin. Standard
      treatment is a standard target (higher dose) tacrolimus and basiliximab, instead of
      thymoglobulin.

      The investigators hypothesize, that a combined approach of early steroid withdrawal and low
      dose tacrolimus in low immunologic risk transplant recipients will be effective in reducing
      the incidence of new onset diabetes mellitus, while maintaining a low risk of acute
      rejection.

      Objective

      The objective of this study is to compare early post-transplant outcomes with the use of low
      target versus standard target Advagraf in de novo kidney allograft recipients of low
      immunologic risk undergoing early corticosteroid withdrawal.

      Research Method

      This is a pilot study. Primary and secondary outcomes are as follows:

      Primary Outcome Composite endpoint of biopsy proven acute rejection and NODAT at 6 months
      post transplantation.

      Secondary Outcomes

        -  Patient survival

        -  Graft survival

        -  Frequency, severity, and treatment of hypertension

        -  Frequency, severity, and treatment of hyperlipidemia (serum total cholesterol, (high
           density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides)

        -  Weight gain

        -  Infections (cytomegalovirus (CMV), opportunistic infections including urinary tract
           infections requiring treatment, pneumonia)

        -  Malignancy, including post-transplant lymphoproliferative disease (PTLD)

        -  Leukopenia

        -  Renal function as measured by serum creatinine and estimated Glomerular Filtration Rate
           (eGFR)

      The primary endpoint will be evaluated by time-to-event Kaplan Meier analysis and by
      Chi-squared analysis of final 6 month data.

      Statistical Analysis

      Sample size and power:

      In the setting of early steroid withdrawal, Woodle et al. reported an acute rejection rate of
      14% with rATG and 24% with an interleukin-2 receptor antibody induction(10). The incidence of
      NODAT was reported at 21% by Woodle, et al., and was reported 10% in the low dose tacrolimus
      arm of the ELITE-Symphony trial. The investigators, therefore expect a combined event rate of
      24% in Group A and 45% in group B. With a power of 0.80 and alpha error of 0.05, the
      investigators determined that the investigators need 72 subjects in each arm to demonstrate a
      20% difference in our composite primary outcome. For this initial pilot study, the
      investigators aim to recruit a total of 30 subjects After receiving informed consent,
      subjects will be randomized on a 1:1 basis to one of the two treatment groups. Subjects who
      discontinue the study prematurely will not be replaced.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2011</start_date>
  <completion_date type="Actual">October 11, 2019</completion_date>
  <primary_completion_date type="Actual">February 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Composite endpoint of biopsy proven acute rejection and NODAT at 6 months post transplantation. NODAT will be defined as either FPG &gt;7.0mmol/L OR symptoms of hyperglycemia and a random plasma glucose of &gt;11.1 OR 2-h plasma glucose &gt;11.1 during an oral glucose tolerance test(OGTT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participant Deaths</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Death of any participant by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Failure</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Any graft failure by the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dialysis Events</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Any dialysis required by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection Events</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Any infection (CMV, opportunistic infections including urinary tract infections requiring treatment, pneumonia) by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospitalization Events</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Any hospitalization by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Malignancy Events</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Any malignancy (including post-transplant lymphoproliferative disease) by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Event</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Any cardiovascular events by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Any Leukopenia Events</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Any leukopenia by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Leukopenia Events on ≥2 Occasions</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Any leukopenia on ≥2 occasions by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight</measure>
    <time_frame>baseline to 6 months post transplant</time_frame>
    <description>Any changes in weight by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR at 6 Months</measure>
    <time_frame>6 months post transplant</time_frame>
    <description>Participant eGFR value by end of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Graft Rejection</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Low target tacrolimus (Advagraf)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard target tacrolimus (Advagraf)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
    <arm_group_label>Low target tacrolimus (Advagraf)</arm_group_label>
    <other_name>Advagraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
    <arm_group_label>Standard target tacrolimus (Advagraf)</arm_group_label>
    <other_name>Advagraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients over 18 years of age who receive a deceased, living unrelated
             or living related donor renal transplant

          2. No history of pre-existing diabetes mellitus

          3. Not using diabetic medications (insulin, hypoglycemic agents) at the time of
             transplantation

          4. Random plasma glucose level &lt;11.1 at the time of transplantation

          5. Peak PRA (panel reactive antibody) &lt;30%

          6. Females capable of becoming pregnant must have a negative pregnancy test at baseline
             and are required to practice an approved method of birth control for the duration of
             the study and for a period of three months following discontinuation of study
             medication

          7. The patient has given written informed consent to participate in the study

        Exclusion Criteria:

          1. Patients with primary non-function

          2. Peak PRA&gt;=30%

          3. Multiple organ transplants

          4. HLA (human leukocyte antigen) identical living donor transplant recipients

          5. Cold ischemia time over 36 hours

          6. Nonheart beating donor kidney recipients

          7. Pediatric donor kidney recipients

          8. Donor age&gt;=65 years

          9. Patients who are known to have a positive hepatitis C serology, who are human
             immunodeficiency virus (HIV) or Hepatitis B surface antigen positive. Laboratory
             results obtained within 6 months prior to study entry are acceptable. Recipients of
             organs from donors who test positive for Hepatitis B surface antigen or Hepatitis C
             will be excluded.

         10. Patients who are Epstein-Barr virus (EBV) negative and are receiving a transplant from
             an EBV-positive donor (mismatch).

         11. Presence of any severe allergy requiring acute (within 4 weeks of baseline) or chronic
             treatment, or hypersensitivity to drugs similar to those used in the study

         12. Patients with systemic infections

         13. Existence of any surgical or medical condition, other than the current transplant,
             which in the opinion of the investigator, preclude enrollment in this trial

         14. Inability to cooperate or communicate with the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jagbir Gill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UBC / Dept of Medicine / Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 21, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <results_first_submitted>November 27, 2019</results_first_submitted>
  <results_first_submitted_qc>February 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2020</results_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jagbir Gill</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Transplant</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Diabetes after transplant</keyword>
  <keyword>Acute rejection prevention</keyword>
  <keyword>New onset diabetes after transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT01265537/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Target Tacrolimus (Advagraf)</title>
          <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
        </group>
        <group group_id="P2">
          <title>Standard Target Tacrolimus (Advagraf)</title>
          <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The discrepancy in the Baseline Analysis Population Description and the Overall Number of Baseline Participants is seen because 28 participants in total completed their baseline assessments.</population>
      <group_list>
        <group group_id="B1">
          <title>Low Target Tacrolimus (Advagraf)</title>
          <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
        </group>
        <group group_id="B2">
          <title>Standard Target Tacrolimus (Advagraf)</title>
          <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" lower_limit="49.2" upper_limit="66.6"/>
                    <measurement group_id="B2" value="50.4" lower_limit="46.6" upper_limit="56.5"/>
                    <measurement group_id="B3" value="54.3" lower_limit="47.1" upper_limit="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian/White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family History of Diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="3.0"/>
                    <measurement group_id="B2" value="27.5" spread="6.3"/>
                    <measurement group_id="B3" value="26.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150" spread="21"/>
                    <measurement group_id="B2" value="159" spread="27"/>
                    <measurement group_id="B3" value="154" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81" spread="9"/>
                    <measurement group_id="B2" value="87" spread="9"/>
                    <measurement group_id="B3" value="84" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cholesterol Medications</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cholestoral</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.56" spread="0.97"/>
                    <measurement group_id="B2" value="4.43" spread="0.60"/>
                    <measurement group_id="B3" value="4.49" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-Density Lipoproteins</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.72" spread="0.82"/>
                    <measurement group_id="B2" value="2.68" spread="0.76"/>
                    <measurement group_id="B3" value="2.70" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-Density Lipoproteins</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.21" spread="0.28"/>
                    <measurement group_id="B2" value="1.37" spread="0.62"/>
                    <measurement group_id="B3" value="1.30" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.38" spread="0.36"/>
                    <measurement group_id="B2" value="1.52" spread="1.08"/>
                    <measurement group_id="B3" value="1.46" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="0.8"/>
                    <measurement group_id="B2" value="5.2" spread="0.6"/>
                    <measurement group_id="B3" value="5.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Random Glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="1.3"/>
                    <measurement group_id="B2" value="5.7" spread="1.1"/>
                    <measurement group_id="B3" value="5.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak Panel-Reactive Antibody (PRA) before transplant</title>
          <description>Panel reactive antibody (PRA) testing is performed on patients prior to transplantation in an effort to identify the potential presence of anti-HLA antibodies and minimize the risk of antibody mediated rejection. The inclusion criteria for this study was a peak PRA &lt;10%.</description>
          <units>%</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="B2" value="0" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="B3" value="0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deceased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="33" upper_limit="53"/>
                    <measurement group_id="B2" value="34" lower_limit="26" upper_limit="56"/>
                    <measurement group_id="B3" value="39" lower_limit="31" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human Leukocyte Antigen (HLA) Matches</title>
          <description>Human Leukocyte Antigen (HLA) testing is done before an organ transplant to find out if tissues match between the donor and the person receiving the transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0 matches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 match</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 matches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 matches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 matches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 matches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection</title>
        <description>Composite endpoint of biopsy proven acute rejection and NODAT at 6 months post transplantation. NODAT will be defined as either FPG &gt;7.0mmol/L OR symptoms of hyperglycemia and a random plasma glucose of &gt;11.1 OR 2-h plasma glucose &gt;11.1 during an oral glucose tolerance test(OGTT).</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection</title>
          <description>Composite endpoint of biopsy proven acute rejection and NODAT at 6 months post transplantation. NODAT will be defined as either FPG &gt;7.0mmol/L OR symptoms of hyperglycemia and a random plasma glucose of &gt;11.1 OR 2-h plasma glucose &gt;11.1 during an oral glucose tolerance test(OGTT).</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant Deaths</title>
        <description>Death of any participant by end of study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant Deaths</title>
          <description>Death of any participant by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Failure</title>
        <description>Any graft failure by the end of the study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Failure</title>
          <description>Any graft failure by the end of the study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dialysis Events</title>
        <description>Any dialysis required by end of study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dialysis Events</title>
          <description>Any dialysis required by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection Events</title>
        <description>Any infection (CMV, opportunistic infections including urinary tract infections requiring treatment, pneumonia) by end of study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection Events</title>
          <description>Any infection (CMV, opportunistic infections including urinary tract infections requiring treatment, pneumonia) by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospitalization Events</title>
        <description>Any hospitalization by end of study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospitalization Events</title>
          <description>Any hospitalization by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Malignancy Events</title>
        <description>Any malignancy (including post-transplant lymphoproliferative disease) by end of study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Malignancy Events</title>
          <description>Any malignancy (including post-transplant lymphoproliferative disease) by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Event</title>
        <description>Any cardiovascular events by end of study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Event</title>
          <description>Any cardiovascular events by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Any Leukopenia Events</title>
        <description>Any leukopenia by end of study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Any Leukopenia Events</title>
          <description>Any leukopenia by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Leukopenia Events on ≥2 Occasions</title>
        <description>Any leukopenia on ≥2 occasions by end of study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Leukopenia Events on ≥2 Occasions</title>
          <description>Any leukopenia on ≥2 occasions by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight</title>
        <description>Any changes in weight by end of study.</description>
        <time_frame>baseline to 6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight</title>
          <description>Any changes in weight by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="0.8" upper_limit="6.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-1.3" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>eGFR at 6 Months</title>
        <description>Participant eGFR value by end of study.</description>
        <time_frame>6 months post transplant</time_frame>
        <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Target Tacrolimus (Advagraf)</title>
            <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
          </group>
          <group group_id="O2">
            <title>Standard Target Tacrolimus (Advagraf)</title>
            <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR at 6 Months</title>
          <description>Participant eGFR value by end of study.</description>
          <population>The discrepancy in the overall number of participants with outcome measure data and the overall number of participants in the participant flow module is seen because 28 participants in total have outcome measure data available.</population>
          <units>mL/min/1.73^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="51" upper_limit="81"/>
                    <measurement group_id="O2" value="51" lower_limit="43" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from the baseline visit until 6 months post transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Target Tacrolimus (Advagraf)</title>
          <description>This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;low-target&quot; Advagraf.
Tacrolimus: Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4</description>
        </group>
        <group group_id="E2">
          <title>Standard Target Tacrolimus (Advagraf)</title>
          <description>This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and &quot;standard target&quot; Advagraf.
Tacrolimus: Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Acute Rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jagbir Gill</name_or_title>
      <organization>St. Paul's Hospital</organization>
      <phone>6046822344 ext 64706</phone>
      <email>JAGill@providencehealth.bc.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

